Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations Cook L; Cooper NDrug Des Devel Ther 2010[Jul]; 4 (ä): 139-45Eltrombopag is one of a number of novel agents recently developed for use in the treatment of patients with immune thrombocytopenia (ITP). Rather than preventing destruction of platelets, these agents increase the production of platelets, presumably overwhelming the immune system resulting in normal platelet counts in individuals refractory to or dependent on other therapies. These treatments are well tolerated and in randomized controlled trials show an improvement in platelet counts and a reduction in bleeding in refractory patients. This article summarizes the development of this new class of drug and evaluates the safety and efficacy of eltrombopag in patients with ITP.|Animals[MESH]|Benzoates/adverse effects/pharmacology/*therapeutic use[MESH]|Blood Platelets/drug effects/metabolism[MESH]|Chronic Disease[MESH]|Humans[MESH]|Hydrazines/adverse effects/pharmacology/*therapeutic use[MESH]|Platelet Count[MESH]|Purpura, Thrombocytopenic, Idiopathic/*drug therapy[MESH]|Pyrazoles/adverse effects/pharmacology/*therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH] |